Skip to content

Monitoring the Clinical and Immunological Effects of Microbiome Changes Following Severe Burn Injury

Monitoring the Clinical and Immunological Effects of Microbiome Changes Following Severe Burn Injury

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07329595
Acronym
microbiome
Enrollment
30
Registered
2026-01-09
Start date
2023-12-01
Completion date
2026-12-31
Last updated
2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gut Microbiota Diversity and Composition, Inflammatory Responses, Severely Burned Patients

Keywords

severe burn injury, gut microbiome

Brief summary

The aim of this study is to longitudinally monitor dynamic changes in the gut microbiome following severe burn injury using fecal samples. Under standard nutritional protocols and intensive care management, serial fecal sampling is performed to assess alterations in microbiome diversity and composition, as well as the indirect effects of these changes on measurable inflammatory biomarkers, endocrine, hematological, immunological, and other organ-specific parameters, the clinical course, and patient outcomes.

Detailed description

Severe burn injury induces stress-related intestinal damage, leading to decreased gut perfusion, cellular injury, increased mucosal permeability, and reduced intestinal motility. These pathophysiological changes facilitate bacterial and endotoxin translocation, making the gut microbiome a major source of endogenous infection. Recent evidence indicates that the gut microbiome plays a critical role in regulating immune responses and supporting post-injury recovery, while also contributing to the development of complications such as sepsis and multi-organ failure. The aim of this study is to longitudinally monitor dynamic changes in the gut microbiome following severe burn injury using fecal samples. Under standard nutritional protocols and intensive care management, serial fecal sampling is performed to assess alterations in microbiome diversity and composition, as well as the indirect effects of these changes on measurable inflammatory biomarkers, endocrine, hematological, immunological, and other organ-specific parameters, the clinical course, and patient outcomes. Clinical outcomes are evaluated based on mortality, length of hospital stay, duration of mechanical ventilation, incidence of secondary infections, rate of bacteremia, organ failure and its severity (assessed using the SOFA score), and wound healing. Upon enrollment, patients undergo rectal swab collection and initial fecal sampling, followed by weekly fecal sample collection one to two times per week, alongside weekly laboratory investigations in addition to standard care. For microbiome analysis, DNA is extracted from fecal samples, followed by PCR amplification of the 16S bacterial rRNA operon. The amplified regions are sequenced, and taxa are identified based on sequence data. Relative abundances of taxa are calculated, and alpha- and beta-diversity metrics are compared within serial samples from individual patients and between patients.

Interventions

None listed

Sponsors

Tamas Vegh, MD
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients (age between 18 and 65 years) meeting the diagnostic criteria for severe burn injury, burns involving more than 20% of the total body surface area (TBSA) and/or inhalation injury. * Burn injury caused by scalding, flame, electrical, contact, or chemical exposure * Hospital admission within 24 hours following injury

Exclusion criteria

* Patients with inflammatory bowel diseases or malignant neoplasms. * Patients with a history of major gastric and/or intestinal resections * Patients in a pre-injury ECOG performance status of 4.

Design outcomes

Primary

MeasureTime frameDescription
The abundance and bio-diversity of gut microbiotaDay of admission, one to two times per week up to 12 weeksGenomic DNA is extracted from the collected samples, followed by PCR amplification of the eubacterial 16S rRNA gene. The amplified region is subsequently sequenced, and taxonomic assignment is performed based on sequence analysis. Following the calculation of relative taxonomic abundances, alpha and beta diversity metrics are compared across longitudinal samples within individual patients and between patients.

Countries

Hungary

Contacts

Primary ContactLenke Jenei Kluch, MD
jenei.kluch.lenke@med.unideb.hu+36303884600
Backup ContactErzsebet Igbonu-Nagy, BSC
nagyboske@med.unideb.hu+36203991551

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026